Conexeu Sciences Inc. CNXU
- Market cap
- $111.7M
- P/E
- 0.0×
Follow CNXU
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | 0 | (4) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | 0 | (4) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.07) | (0.31) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.03) | (0.13) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.03) | (0.13) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.01 | 0.58 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 7 | 13 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | 0 | (2) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | — | 0 | (2) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 0 | 7 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | 0 | (5) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 0 | 7 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (95.43%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (98.33%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (105.36%) |
ROE
|
|||
Conexeu Sciences Inc. (CNXU) key facts
- Conexeu Sciences Inc. reported a net loss of $3.9 million, or a loss of $0.31 per share, for fiscal 2025.
- As of September 25, 2026, CNXU traded at $3.89, a market capitalization of $111.7 million.
- Return on equity was −105.4% and debt-to-equity 0.00.
Conexeu Sciences Inc. (CNXU) Latest News
18 Aug
Conexeu Sciences identifies emerging regeneration category in medical aesthetics as research priorities shift. New category positioning signals major strategic opportunity likely to reshape company trajectory in medical aesthetics.
3 Aug
Conexeu Sciences CEO Miles Harrison addresses the company's role in the emerging GLP-1 billion-dollar market during a fireside chat. CEO discussion of major GLP-1 market positioning signals strategic moves that could significantly shift company trajectory and investor sentiment.
14 Jul
GLP-1 drugs are generating a new $2 billion aesthetics market opportunity, and Conexeu Sciences is building products to target it. Conexeu targets a newly created $2 billion aesthetics market tied to GLP-1 drug side effects.
7 Jul
The $190 billion weight-loss boom reveals a tissue-restoration gap that existing injectables cannot address, creating opportunity for Conexeu Sciences Inc. (CNXU). CNXU is positioned to address the tissue restoration gap exposed by weight-loss treatments.
25 Jun
Conexeu Sciences Inc. (CNXU) opens Vancouver R&D facility to advance regenerative tissue platform. R&D facility opening supports platform development with moderate effects on operations and positioning.
19 Jun
Conexeu Sciences Inc. (CNXU) is making CXU platform moves that quietly redefine its commercial ambitions. CXU platform moves signal major strategic shifts likely to alter company trajectory and investor views.
15 Jun
Conexeu Sciences Inc. (CNXU) appoints five new members to its board, executive team, and advisory roles after its Nasdaq listing. Five leadership appointments strengthen governance and expertise post-Nasdaq entry without fundamentally shifting operations or market trajectory.
8 Jun
Conexeu Sciences Inc. (CNXU) reports manufacturing scale up and regulatory progress for its lead CXU wound care program. Manufacturing scale-up and regulatory progress on the lead wound care program enable expanded production and faster commercialization.
2 Jun
Conexeu Sciences (CNXU) advances 3D-printed bioregenerative breast matrix initiative, drawing investor reactions to the development. 3D-printed breast matrix launch signals major product innovation likely to shift company trajectory and sentiment.
27 May
Conexeu Sciences initiates preclinical development program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform in collaboration with Wake Forest Institute for Regenerative Medicine. Early preclinical collaboration advances core platform development with moderate effects on innovation pipeline and market positioning.
21 May
Conexeu Sciences Inc. commences trading on Nasdaq under ticker symbol CNXU. Nasdaq listing marks a major milestone that boosts visibility, liquidity and investor access for the company.